Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q2- Text added to 2020 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
adenocarcinoma, aprpoved, Area, banc, BCBSA, BCBSM, bevacizumab, Blue, BSC, candidate, carcinoma, cardiomyopathy, clear, conventional, curative, cytarabine, cytokine, DAYBREAK, deucravacitinib, DNA, Dragonfly, driven, durable, electronic, en, epidermal, fibrotic, gastroesophageal, HCSC, hypertrophic, identification, IDHENTIFY, Idhifa, incidence, infection, inspection, instability, intensive, invented, IRS, isocitrate, junction, Korea, lab, link, lowest, mavacamten, microsatellite, MyoKardia, neuroinflammation, obstructive, occurrence, Onureg, Organisation, PASI, pathologic, percent, petition, plaque, POETYK, political, quantity, reconsider, RNA, rulemaking, SCLC, score, Secretary, sensitizing, Shield, sNDA, South, sPGA, static, sued, surgery, Taiwan, translocation, unlimited, unspecified, unused, urothelial, withdrawn
Removed:
analgesic, cellular, concomitantly, designation, Gulf, medication, objective, Perfalgan, updated
Valuein 2020 Q2 filing- Value in 2020 Q3 filing
Original filings
Filing view